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OBJECTIVE — A randomized trial with 1-year follow-up was conducted in 23 general prac-
tices to study the relationship between target values for glycemic control and well-being in type
2 diabetes.
RESEARCH DESIGN AND METHODS — A total of 176 patients with type 2 diabetes,
aged 40-75 years, were included. General practitioners were encouraged to make decisions
according to a standardized step-up regimen until the target level of glycemic control was
reached. The random allocation to a strict or a less strict target level of glycemic control (fast-
ing capillary glucose <6.5 or <8.5 mmol/1), change in HbAlc and fasting glucose, and initiat-
ing insulin or treatment with oral hypoglycemic agents were studied as putative determinants
of scores on a type 2 diabetes symptom checklist, a profile of mood states, an affect balance scale,
and general well-being. Adjustments were made for baseline scores on the outcome at issue.
RESULTS— Positive affect (an odds ratio [OR] [95% CI] of 0.39 [0.19-0.83]) and perceived
treatment burden (OR 0.48 [0.23-0.98]) were unfavorably altered in the group randomly allo-
cated to stricter target levels (fasting capillary glucose <6.5 mmol/1). Patients who had a
decrease in HbAic of 1% or more tended to have comparatively favorable mood (OR displea-
sure score 0.35 [0.13-0.94]) and general well-being scores at 1 year (ORs of having unfavor-
able scores ranged from 0.4 to 0.5, NS).
CONCLUSIONS — Perceived treatment burden and positive effect are unfavorably affected
by random allocation to a strict target level for glycemic control. Improved glycemic control
is associated with favorable mood and possibly general well-being in type 2 diabetes.
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Sustained improvement in health is rec-ognized as an important goal in dia-betes care. Among the primary
objectives of treatment are relief of symp-
toms and improvement of quality of life
(1,2). In practical diabetes care, a trade-off
often has to be made between beneficial
and adverse effects of strict glycemic control.
Prevention of chronic complications requires
glycemic levels as close to normal as possible
(3). However, if hypoglycemic episodes
occur, and if the treatment regimen is expe-
rienced as burdensome, quality of life could
be improved by less strict glycemic control.
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The objective of the present study was
to establish the relationship between target
level of glycemic control, glycemic improve-
ment, and other aspects of treatment on the
one hand, and several measures of well-
being on the other hand, in type 2 diabetes.
The study was designed as a randomized
clinical trial, comparing the effects of a strict
glycemic target level with a less strict target
level, within the same management proto-
col, situated in general practice. Although
this design did not yield a meaningful
glycemic contrast, it did allow us to study
the effects of allocation to strict target levels
on well-being experimentally. The influence
of changing glycemic levels on well-being,
given the absence of an experimental
glycemic contrast at 1 year, could be stud-
ied prospectively by analysis of within-sub-
ject changes in the study cohort as a whole.
Based on previous research at our insti-
tution, we anticipated a beneficial effect of
good glycemic control on both physical
symptoms and emotional well-being (as long
as no unacceptable hypoglycemic episodes
occur) (4). However, if improvement of
glycemic control requires initiation of more
intensive modes of treatment (such as taking
oral hypoglycemic agents [OHAs] instead of
only lifestyle measures, or injecting insulin
instead of only taking OHAs), we would
logically expect this to hamper well-being, as
was found by Jacobson et al. (5). Other stud-
ies, some reporting only in passing on this
issue, remain inconclusive (6—11).
Differences in study populations and
methods of assessment may be held
accountable for inconsistent results of pre-
vious studies on glycemic control, treat-
ment modality, and quality of life in type 2
diabetes. Using only a general, albeit mul-
tidimensional, quality-of-life instrument
(and often only including men), other stud-
ies in this field have not provided conclu-
sive results as to the relationship between
improvement of glycemic control and well-
being (6,12-14). Acknowledging the
necessity for a multidimensional approach
and expecting subtle changes over time in
a relatively healthy population, we have
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chosen to measure the various aspects of
subjective well-being using as specific and
sensitive instruments as possible. We
addressed symptoms related to diabetes,
emotional well-being, positive as well as
negative affect, and overall evaluations of
well-being and satisfaction.
RESEARCH DESIGN AND
METHODS — A randomized trial was
performed, allocating participants to either
group 6 or group 8. For patients in group
6, the glycemic target level was a fasting
capillary glucose <6.5 mmol/1; for patients
in group 8, the target level was <8.5
mmol/1. The treatment itself did not differ
between these groups; the only difference
was the fasting glucose level below which
no glucose-lowering measures were to be
taken by the participating general practi-
tioners (GPs). Because the Dutch treatment
standard exclusively considered fasting glu-
cose values for daily practice, we informed
the GPs that corresponding targets for
HbAlc in groups 6 and 8 should be about 6
and 8%, respectively. All GPs were encour-
aged to make treatment decisions accord-
ing to a standardized step-up regimen
based on a widely used treatment standard
of the Netherlands College of General Prac-
titioners (15). Additional features of the
regimen were a stepwise protocol for initi-
ation of insulin therapy by the GP and the
direct availability to the GP of education
facilities for insulin therapy. The regimen
had the usual buildup: tablets were to be
prescribed, if necessary, considering the
fasting glucose target value, and dosages
increased up to their usual maximum
before other glucose-lowering agents were
added. In patients with a BMI >27 kg/m2,
metformin was the first step. If the assigned
glucose target value was not reached, a sul-
fonylurea (either glibenclamide, gliclazide,
or glipizide) was to be added. In patients
with a BMI <27 kg/m2, metformin was not
considered indicated, so a sulfonylurea was
the first step. If the assigned target value
was not reached on tablets alone, bedtime
intermediate-acting insulin was added (and
metformin, if any, discontinued). If the tar-
get value was not reached with this combi-
nation therapy, a sulfonylurea was to be
discontinued and twice-daily injections of a
mixture of short- and intermediate-acting
insulin was to be started.
At the study center, glycemic control
was assessed three times a month. Both
fasting glucose and HbAlc were reported to
the GP All patients were requested to con-
tact their GP 2 weeks after each visit to the
study center for obtaining therapeutic
advice according to the step-up regimen.
The duration of follow-up was 1 year. The
ethics committee of our university approved
the study protocol.
Patients
Assessment of eligibility of potential partici-
pants was done by an initial file survey and
by subsequently including incident cases
between June 1992 and February 1994 in
23 practices (27 GPs) out of a total of 26
general practices in Hoorn, the Netherlands.
GPs were asked to identify all their patients
with type 2 diabetes aged between 40 and
75 years and of Caucasian ethnicity. A total
of 347 patients were identified. Of these, 51
met one of the following exclusion criteria:
no established diagnosis of diabetes accord-
ing to World Health Organization criteria in
the absence of glucose-lowering medication
(n = 4); carcinoma (n = 6); other comorbid-
ity preventing three monthly visits to the
study center (n = 17) or seriously impairing
well-being (n = 8); language problems (n =
5); GP objected to participation of patient
because of psychological problems (n = 11).
Thus, 296 potential participants—
86% of all Caucasian patients with type 2
diabetes within the eligible age range—
were invited. Of these, 229 (77%) gave
written informed consent. Thirty people
(13%) not treated with blood glucose-low-
ering medication and with a fasting capil-
lary glucose <6.7 mmol/1 and an HbAlc
^6 .1% at baseline were regarded as prob-
ably nondiabetic and excluded from the
study, because they were not expected to
contribute to our experimental contrast at
1-year follow-up. Thus, 199 patients were
randomized to either group 6 (n = 101) or
group 8 (n = 98), of whom 176 had suffi-
cient data to be analyzed at 1 year.
Methods
Determinants and potential con-
founders. HbAlc (reference 4.3-6.1%) was
determined by ion-exchange high-perfor-
mance liquid chromatography. Capillary
whole blood glucose level was assessed
with a portable blood glucose monitor
(One Touch II; LifeScan, Milpitas, CA). The
same devices were used in all participating
practices. At each visit, the use of blood
glucose-lowering drugs was recorded, and
weight was measured.
In a previous cross-sectional analysis,
the relationship between glycemic control
and well-being often was apparent only in
patients with lower neuroticism scores (i.e.,
more adequate patients). In this study, the
Netherlands Personality Questionnaire was
administered (16). Its neuroticism scale con-
sists of 21 items reflecting tendencies toward
vague fears, vague physical signs, depressed
mood, and feelings of insufficiency, resulting
in a score with a theoretical range from 0 to
42. People with high scores on this scale are
known to report more symptoms and can be
described as generally emotional, tense, inse-
cure, or gloomy. Tested in various popula-
tions, the neuroticism scale was shown to
have an average internal consistency coeffi-
cient (a) of 0.86 and a test-retest reliability
between 0.77 and 0.86 (16). It was not fea-
sible to assess personality before the start of
the study Forced by the length of the ques-
tionnaire and the possibility of mutual inter-
ference of the personality and well-being
assessments, we chose to postpone the per-
sonality assessment, more stable as a concept
and as a questionnaire, until 6 months into
the study.
A cardiovascular history was considered
to be present if the patient reported a
myocardial infarction or a stroke to have
taken place at any time in the past; if angina
pectoris had been confirmed by a cardiolo-
gist; if a transient ischemic attack had been
diagnosed by a GP or a neurologist; or if typ-
ical intermittent claudication, according to a
standard questionnaire (17), was present.
Assessment of well-being. The following
questionnaires concerning well-being were
administered during the baseline and 1-
year visits to the study center. We used the
type 2 diabetes symptom checklist (DSC-
type 2) (18) to measure the presence and
perceived burden of diabetes-related symp-
toms. The DSC-type 2 refers to the month
preceding the visit. It consists of 34 items
divided over eight scales: hyperglycemic,
hypoglycemic, neuropathic pain symptoms,
sensibility symptoms, fatigue, cognitive dis-
tress, cardiovascular, and ophthalmologi-
cal. Each item is scored on a frequency scale
and, if a symptom is present, also on a dis-
comfort scale. Multiplication of frequency
by its corresponding discomfort score yields
weighted scores for each scale. In this analy-
sis, weighted scores were used.
The Dutch shortened version of the
profile of mood states (POMS) (19) was
used to measure emotional well-being. The
POMS (32 items) consists of four negative
scales (depression, anger, tension, fatigue)
and one positive scale (vigor), referring to
"the past few days, including today." From
these scales, an aggregate mood score can
2086 DIABETES CARE, VOLUME 21, NUMBER 12, DECEMBER 1998
van der Does and Associates
be calculated. A more accurate measure of
mood state, assumed to be less influenced
by physical fatigue, is the displeasure scale,
which was computed as the sum of the
depression, anger, and tension scores.
In addition to the POMS, which pre-
dominantly measures negative affect, the
widely used affect balance scale (ABS) was
administered. The ABS is a 10-item scale
that measures happiness, covering both
positive and negative aspects (20). In our
study, it referred to the previous 3 weeks.
All scores on DSC-type 2, POMS, and ABS
were transformed to a 0-10 scale, with
lower scores indicating higher levels of
well-being.
Referring to the previous 3 months,
subjects were asked to score their perceived
health ("How would you describe your cur-
rent state of health?") and to give two over-
all evaluations of their quality of life ("How
did you feel, all things considered?" "How
satisfied were you, all things considered,
with your life?") on a 5-point Likert scale.
In addition, patients were asked to indicate
on a 4-point Likert scale the perceived bur-
den of their diabetes treatment. All ques-
tionnaires were introduced to the patients
by the first author and completed by the
patients themselves at the study center.
At each visit to the study center, refer-
ring to the previous 3 months, patients were
asked if they had experienced any episodes
of sweating, weakness, hungriness, dizzi-
ness, etc. If these symptoms had disap-
peared shortly upon taking carbohydrate in
any form, they were taken to indicate an
episode of hypoglycemia. Hypoglycemia
was recorded if the episodes did not occur
just before a planned meal or in connection
with unusual physical exertion (grade 2)
and if help from others had been necessary
to regain normoglycemia (grade 3).
Statistical analysis. Because of skewed
distributions of most outcome measures
and/or a substantial proportion of 0 scores,
linear regression analysis could not be per-
formed (not even after log transformation
of scores), as judged from the distribution
of the residuals. Therefore, the 1-year levels
of all well-being scores were made dichoto-
mous, so that logistic regression analyses
could be performed. This dichotomization
generally took place at the median value of
the levels at baseline (where 0 indicates a
score below the median, and 1 indicates a
score above the median). The four overall
subjective evaluations were dichotomized
between the two most commonly encoun-
tered categories. In logistic regression
analysis, the influence of a determinant can
be expressed as the odds ratio (OR), adjust-
ing for confounding by all the other deter-
minants in the model (21). The SEMs of
the regression coefficients and, if necessary,
covariances were used to obtain the 95%
CIs of the ORs.
The baseline level of each outcome
measure and neuroticism was found to be
strongly (and independently) related to the
level of almost all outcome measures.
Therefore, these variables were included as
standard control variables in all subsequent
analyses.
Initially, we considered the associations
between all outcome measures and the ran-
domization group (group 6/group 8; inten-
tion-to-treat analysis). Subsequently, while
the randomization group remained
included as an additional standard variable
in all analyses, the strengths of the follow-
ing potential determinants of well-being
were investigated separately: a decrease in
HbAlc by > 1% (HbAlc decrease, yes/no); a
decrease in glucose level by ^1.5 mmol/1
(glucose decrease, yes/no); and initiation of
a more intensive treatment modality
(tablets started, yes/no; insulin started,
yes/no). Finally, we included both an HbAlc
decrease and initiation of a more intensive
treatment modality in the same logistic
model to investigate their mutually inde-
pendent relationships with the outcome
measures.
As potential confounders, sex, age,
duration of diabetes, and cardiovascular
history (yes/no) were included in all mod-
els one by one and retained in the model if
confounding was considered to be present
(i.e., if the magnitude of the OR of a pri-
mary determinant was changed by >20%
upon inclusion of the variable) or if inclu-
sion yielded smaller SEMs of the coeffi-
cients of the primary determinants. Product
terms of an HbAlc decrease with age, sex,
baseline HbAlc, and neuroticism were sta-
tistically tested one by one (at the 95% CI)
to investigate the relationship between an
HbAlc decrease and all outcomes at differ-
ent levels of these potential determinants
(effect modification). Before calculating
product terms, the component variables
were centered whenever necessary to pre-
vent collinearity. While testing the signifi-
cance of the product terms, the component
variables were retained in the models.
RESULTS — Follow-up was completed
by 183 out of 199 participants (92%). Eight
patients dropped out of the study because
they found it too burdensome to make
three-monthly visits to the study center (not
because of particularly bad glycemic con-
trol). Six patients were lost to follow-up
because they moved out of the area or
stopped showing up because of illness unre-
lated to diabetes, and two patients died. In
total, 176 (96%) patients had sufficient data
to be included in the analyses. We addition-
ally had to exclude two subjects from the
analyses: at the baseline or 1-year visit, major
life events had influenced their quality of life
such that inclusion would disturb many
analyses. For those who completed follow-
up, attendance at follow-up visits at the
study center was virtually 100%. Compli-
ance with our encouragement to visit the GP
after each of the study visits was probably
less satisfying, which is discussed in a com-
panion manuscript (FE.E.v.d.D., J.N.D.d.N.,
R.J.H., J.H. Dekker, L.M.B., unpublished
observations).
At 1 year of follow-up, treatment had
been intensified more in group 6 than in
group 8. In group 6, 53% of patients had
taken one or more treatment steps, com-
pared with 40% in group 8 (P = 0.001,
adjusted for baseline glycemic level). In spite
of this, no significant difference in glycemic
level between groups 6 and 8 had been
established. In group 6 (n = 93), mean (±
SD) HbAlc and fasting glucose decreased
nonsignificantly from 7.2 ± 1.5 to 7.1 ±
1.2% (P = 0.15) and from 7.8 ± 2.1 to 7.4 ±
1.8 mmol/1 (P = 0.06), respectively. In group
8 (n = 81), HbAlc and glucose values were
already higher than those in group 6 at base-
line (P = 0.04 and 0.02, respectively) and
decreased significantly from 7.8 ± 2.0 to 7.4
± 1.5% (P = 0.005) and from 8.7 ± 2.8 to 7.3
±2.1 mmol/1 (P < 0.001), respectively.
Table 1 shows baseline characteristics
and changes during follow-up of the total
population as well as for those who experi-
enced an HbAic decrease of S:l% com-
pared with those who did not. In addition,
the same data are presented for the sub-
group of the total population in whom
insulin treatment was started during follow-
up. The cut-off level of an HbAic decrease of
5:1% is depicted in Fig. 1 ( ), which
shows the HbAlc change for all patients,
stratified for treatment modality initiated
during follow-up. As can be seen in Table 1,
patients with a ^ 1 % HbAlc decrease, com-
pared with those without, were in less
favorable glycemic control (P < 0.001) and
less intensively treated at baseline. In the
subgroup of the study population in which
insulin treatment was initiated (n = 15), a
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Table 1—Baseline characteristics and follow-up experience of the total population, of the population divided by two levels of an HbAlc decrease,
and of the subgroup in whom insulin treatment was started during follow-up
n
% Male
Age (years)
Diabetes duration (years)
Neuroticism >75th percentile (%)
Baseline treatment (%)
Diet only
OHA
OHA + insulin
Treatment at 1 year (%)
Diet only
OHA
OHA + insulin
Baseline HbAlc (%)
A HbAlc (%)
Baseline fasting capillary glucose (mmol/1)
A Glucose (mmol/1)
Baseline BMI (kg/m2)
A BMI (kg/m2)
Hypoglycemia (grade 2) (%)
3 months preceding baseline
3 months preceding visit at 1 year
Cardiovascular history (%)
Total
174
44.8
63.6 ±8.3
4.0 (2.0-8.4)
24.7
26.4
55.8
17.8
16.7
57.5
25.9
7.5 ±1.8
-0 .3 ±1.1
8.2 ±2.4
-0 .9 ±2.3
28.3 ±3.8
+0.1 ±1.3
8.0
7.5
21.3
HbAlc decrease of < 1.0%
132
44.7
63.9 ±8.2
3.4(1.9-8.0)
23.5
24.2
57.6
18.2
19.7
56.1
24.2
6.9 ±1.2
+0.2 ±0.7
7.5 ±1.8
-0 .3 ±1.9
28.0 ±3.7
+0.1 ±1.2
9.8
6.8
20.4
HbAlc decrease of >1.0%
42
45.2
62.7 ±8.7
5.3 (2.6-8.7)
28.6
33.3
50.0
16.7
7.1
61.9
31.0
9.5 ±1.8
-1 .8 ±0.8
10.4 ±2.9
-2 .6 ±2.8
29.4 ±4.0
+0.0 ±1.5
2.4
9.5
23.8
Insulin started
15
26.7
63.4 ±8.5
5.3 (2.6-13.3)
33.3
0.0
100.0
0.0
0.0
0.0
100.0
9.4 ±2.0
-0 .7 ±1.3
10.7 ±3.0
-3 .3 ±2.9
30.9 ±4.3
+ 1.1 ±1.3
0.0
6.7
26.7
Data are means ± SD, median (interquartile range [i.e., between the 25th and 75th percentiles]), c
to regain normoglycemia) did not occur. A cardiovascular history included myocardial infarction
tent claudication. A, change during follow-up.
6, or n. For hypoglycemia, grade 3 (help from others necessary
angina pectoris, stroke, transient ischemic attack, or intermit-
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Figure 1—HbAlc at baseline and at 1 year. , the cut-off level between an HbAlc decrease of^l%
and no decrease, as used in the analyses. In the reference group, treatment with neither OHAs nor insulin
was started. YfN, yes/no. • , Tablets started; O, insulin started; D, reference.
substantial decrease in fasting glucose (P =
0.001) and HbAlc values (P = 0.05) was
attained (Table 1, right column). As
expected, these patients, on average, gained
some weight during follow-up (P = 0.007).
No hypoglycemic complaints more severe
than grade 2 were reported at baseline or
during follow-up.
In Table 2, baseline and follow-up data
on selected outcome measures are given for
the same groups as in Table 1. In this rela-
tively healthy study population, median
scores at baseline on the three question-
naires (first six rows) were low, indicating
that many patients reported satisfactory
well-being. Although mean changes of
these scores during follow-up are also
small, the reported SDs indicate that sub-
stantial changes did take place. Scoring
percentages on the four separate items after
follow-up, as compared with baseline,
seem to be consistent with the changes on
the three questionnaires.
By calculating rank-correlations between
neuroticism and well-being scores at base-
line, it was confirmed that people with high
neuroticism scores tend to report more
symptoms (r = 0.47 for DSC total, P <
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Table 2—Baseline levels and mean change during follow-up of selected measures of well-being for the total population, for the population
divided by two levels of an HbAlc decrease, and for the subgroup in whom insulin treatment was started during follow-up
DSC-type 2, hyperglycemic score
At baseline
Change over 1 year
POMS, displeasure score
At baseline
Change over 1 year
ABS, total score
At baseline
Change over 1 year
How did you feel . . .?(% "good" or better)
At baseline
At 1 year
How would you describe . . . health . . . ?
(% "good" or better)
At baseline
At 1 year
How satisfied were you with your life . . . ?
(% "satisfied" or more)
At baseline
At 1 year
How burdensome . . . treatment. . . diabetes?
(% more than "not burdensome")
At baseline
At 1 year
Total
0.6 (0.0-2.5)
-0 .2 ±1.8
0.7(0.2-1.4)
+0.1 ±1.1
2 (1-3)
-0.2 ±2.0
73.1
74.7
64.9
71.9
83.0
79.5
39.2
38.6
HbAlc decrease of <1.0%
0.6 (0.0-2.3)
+0.0 ±1.6
0.7(0.1-1.4)
+0.2 ± 1.1
2 (1-3)
-0 .1 ±1.9
76.9
73.1
69.9
70.2
84.6
77.1
42.3
40.5
HbAlc decrease of > 1.0%
0.6 (0.0-4.4)
-0 .8 ±2.1
0.8 (0.4-1.7)
-0 .1 ±1.3
2 (1-3)
-0 .5 ±2.2
61.0
80.0
51.2
77.5
78.0
87.5
29.2
32.5
Insulin started
1.0(0.4-3.8)
-0 .9 ± 3.0
1.5 (0.4-3.2)
+0.8 ±1.4
3 (2-4)
+0.1 ±3.0
53.3
40.0
33.3
46.7
66.7
60.0
60.0
53.4
Data are means ± SD, median (interquartile range), or proportions. All scores on the questionnaires were transformed to a 0-10 scale, where higher scores are
unfavorable.
0.001). As expected, high scores were also
associated with worse emotional well-being
(r = 0.57 for POMS displeasure, P < 0.001),
general well-being (r = 0.28, P < 0.001), sat-
isfaction (r = 0.21, P = 0.006), and perceived
health (r = 0.24, P = 0.002).
Logistic regression analyses
ORs >1.00 indicate that the determinant
(allocation to group 8, HbAlc decrease, or
insulin started) is associated with unfavor-
able well-being; ORs <1.00 indicate the
opposite. CIs not including 1.00 are statis-
tically significant at the 5% level. In our
analysis of the randomization group, allo-
cation to group 8 (i.e., a less strict glycemic
target level) was significantly more favorable
than allocation to group 6 with regard to
whether the treatment was experienced as
burdensome (OR [95% CI] 0.48
[0.23-0.98]) and with regard to the positive
scale of the ABS (OR 0.39 [0.19-0.83]). In
addition, there were trends toward a favor-
able effect of allocation to a less strict
glycemic target in the overall subjective
evaluations of general well-being (OR 0.51
[0.23-1.15]) and perceived health (OR 0.46
[0.21-1.04]). Additional adjustment for
baseline HbAlc—considered necessary
because of the 0.6% difference at baseline
between the randomization groups—did
not affect these results. We found no effects
of the randomly allocated target value with
regard to scores on POMS or DSC-type 2.
Table 3 shows relationships, expressed
as ORs (with 95% CIs) adjusted for base-
line level of the outcome, neuroticism, and
randomization group, of an HbAlc decrease
and of insulin being started with all out-
come measures. Focusing on psychological
well-being (POMS, ABS, and overall evalu-
ations of well-being), almost all ORs asso-
ciated with an HbAlc decrease are <1.00,
while almost all ORs associated with
insulin being started are >1.00. Consid-
ered separately, however, few ORs are
significant in statistical terms. Furthermore,
the 95% CIs of the ORs associated with
insulin being started, are wide, which is
related to the small number of insulin
starters (n = 15). Tablets being started did
not significantly affect any outcome meas-
ure in our study (data not shown), despite
a mean improvement in HbAlc of 1.2% (P
< 0.001) in that subgroup. The relation-
ships of the glucose decrease with the out-
come measures hinted in the same
direction as was found for the HbAlc
decrease, only to a statistically less signifi-
cant degree (data not shown).
Overall, none of the DSC-type 2 scales
is influenced by an HbAlc decrease, except
for a relative increase in neuropathic sensi-
bility symptoms (Table 3). However, statis-
tically significant product terms for an
HbAlc decrease and age ^70 years (yes/no)
showed that associations of the HbAk.
decrease with the hyperglycemic and the
cardiovascular scales of the DSC-type 2
were different for people ^70 years of age
compared with the rest of the population. In
the older age-group (n = 48), there were
beneficial relationships between the HbAlc
decrease on the one hand and cardiovascu-
lar score (OR 0.18 [0.06-0.55]) and hyper-
glycemic score (OR 0.20 [0.06-0.64]) on
the other hand, whereas in the rest of the
population, no relationships were found
(OR 1.68 [0.59-4.80] and OR 1.41
[0.51-3.89], respectively). Considering the
fact that the hypoglycemic scale of the DSC-
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Table 3—Overall relationships of an HbAlc decrease (^1%; yes/no) and initiation of insulin
treatment (yes/no) during follow-up with all outcome measures
DSC-type 2
Fatigue
Hyperglycemic
Neuropathic sensibility symptoms
Neuropathic pain symptoms
Ophthalmological
Cardiovascular
Cognitive distress
Hypoglycemic
POMS
Depression
Anger
Tension
Subtotal: displeasure score
Vigor
Fatigue
Total
ABS
Positive
Negative
Total
General well-being
How did you feel. . . ?
How satisfied were you with your life . . . ?
How would you describe . . . health . . . ?
How burdensome . . . treatment. . . diabetes?
HbAic decrease
1.17(0.46-2.98)
0.84 (0.35-2.01)
2.37(1.05-5.37)
0.71 (0.28-1.77)
0.88 (0.39-2.00)
0.96 (0.39-2.38)
1.40(0.54-3.64)
0.69 (0.29-1.63)
1.13(0.45-2.85)
0.46(0.18-1.14)
0.77(0.31-1.91)
0.35(0.13-0.94)
1.45 (0.65-3.24)
0.71 (0.28-1.81)
1.02 (0.38-2.74)
0.53(0.22-1.28)
0.52(0.17-1.61)
0.49(0.19-1.24)
0.54(0.19-1.49)
0.39(0.12-1.23)
0.51 (0.19-1.37)
0.83 (0.36-1.94)
Insulin started
1.27(0.27-5.96)
0.36(0.09-1.51)
4.43(1.17-16.7)
2.72 (0.70-10.6)
0.78 (0.22-2.73)
1.06(0.25-4.42)
2.80 (0.59-13.2)
3.13(0.82-11.9)
4.14(0.88-19.6)
1.56(0.37-6.50)
3.82 (0.75-19.4)
1.25 (0.26-6.06)
4.12(1.08-15.7)
0.96(0.21-4.34)
2.10(0.40-10.9)
1.31 (0.38-4.46)
0.56(0.10-3.09)
1.17(0.31-4.43)
3.73 (1.00-14.0)
1.49 (0.37-5.99)
1.72 (0.46-6.37)
1.62 (0.47-5.64)
Data are OR (95% CI). ORs >1.00 indicate unfavorable well-being; ORs <1.00 indicate favorable well-
being; dichotomization took place at the median of the baseline values. All ORs are adjusted for baseline
level of the outcome measure at issue, neuroticism, and randomization group.
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Figure 2—Associations between an HbAlc decrease and the scores on the POMS at 1 year. ORs with
95% CIs were adjusted for the effects of changes in treatment modality, baseline level of the outcome
measure at issue, neuroticism, and randomization group. Outcome measures were dichotomized at the
baseline median value.
type 2 contains no real physical signs, we
also performed logistic regression analysis
with self-reported hypoglycemic complaints
in the 3 months preceding the 1-year visit as
the outcome measure. This analysis yielded
no significant findings. The frequency of
hypoglycemia was, however, low (Table 1).
In Fig. 2, ORs and 95% CIs are shown
for the associations between an HbAlc
decrease and the scores on the POMS,
independent of (i.e., adjusted for the effects
of) changes in treatment modality. An
HbAlc decrease is associated with favor-
able scores on the displeasure scale (OR
<1.00), while the (statistically nonsignifi-
cant) associations with scores on the three
components of this scale (depression,
anger, and tension) at least exhibit the same
direction. The product term for an HbAlc
decrease and gender proved to be statisti-
cally significant in the model of the tension
scale of the POMS: for men, no relation was
found between an HbAlc decrease and ten-
sion (OR 1.77 [0.48-6.6]); for women with
an HbAlc decrease, however, there tended
to be a concordant decrease in tension
score (OR 0.29 [0.08-1.05]).
Adjusted ORs and 95% CIs for associ-
ations between the HbAlc decrease on the
one hand and the ABS and the four sepa-
rate questions on general well-being on the
other hand, are presented in Fig. 3. In these
general well-being scores, trends consis-
tent with the findings in the POMS dis-
pleasure scale are apparent.
The associations between an HbAlc
decrease, tablets being started, and insulin
being started on the one hand and the
measures of well-being on the other were
not substantially influenced by mutual
adjustment of the determinants. For the
HbAlc decrease, this can be seen by com-
parison of the ORs in Table 3, left column,
and the mutually adjusted ORs in Figs. 2
and 3. Apart from the interactions described
above, no effect modifications by age, gen-
der, baseline HbAlc, or neuroticism were
identified. Additional adjustments for con-
founding were not necessary. Our results
did not change substantially as a result of
dichotomization of the outcome measures
at the 75th percentile instead of the median.
The larger number of items in the dis-
pleasure score of the POMS—which we con-
sider to be our most accurate measure of
mood state—and the accompanying
smoother distribution of values made it pos-
sible to perform the more accurate and pow-
erful method of linear regression analysis for
this particular score, which lacks the neces-
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Figure 3—Associations between the HbAlc decrease and scores on the ABS and overall evaluations of
well-being at 1 year. ORs with 95% CIs were adjusted for change in treatment modality, baseline level
of the outcome measure at issue, neuroticism, and randomization group. Outcome measures were
dichotomized at the baseline median value (ABS) or between the two most commonly encountered
responses (overall evaluations).
sity of collapsing the outcome by
dichotomization. As expected, the associa-
tion of an HbAlc decrease with mood was
confirmed by this linear regression analysis
(P = 0.01); an HbAlc decrease explained
2.4% of the variation in the displeasure
scores that remained after adjustment for
baseline levels. Adjusted displeasure scores of
patients with an HbAlc decrease were 15%
(95% CI: 4-26%) lower than those of
patients without, while adjusted scores of
patients who started insulin were 29%
(7-57%) higher than the scores of those who
did not. Again, the contribution of tablets
being started was nonsignificant (P = 0.9).
CONCLUSIONS— This experiment
involved random allocation to a stringent or
a less stringent target for fasting glucose in
type 2 diabetic patients. Random allocation
to the more stringent target level (fasting
glucose <6.5 mmol/1, group 6), as opposed
to accepting somewhat higher glucose lev-
els (group 8), appeared to be associated
with a greater perceived burden of treat-
ment and less positive affect. By design,
and despite better glycemic control at base-
line, treatment was intensified in signifi-
cantly more patients in group 6 compared
with group 8. However, the proportion of
patients with glucose values below the tar-
get value rose only slightly from 28 to 31%
in group 6, while in group 8, this percent-
age rose from 59 to 80% (data not shown).
We assume that our study design led to a
more rigid adherence to treatment goals,
which implies that allocation to a strict tar-
get value would be more frustrating, prob-
ably to both patient and doctor. Therefore,
it might be postulated that the adverse effect
of target levels is attributable only to patients
who were not able to reach their assigned
target level during follow-up. On post hoc
stratified analysis, this appeared to be the
case for positive affect but not for perceived
burden of treatment (data not shown). This
suggests that reaching strict target levels
may diminish unhappiness but does not
necessarily make patients perceive the treat-
ment as less burdensome.
A relevant difference in HbAlc between
groups 6 and 8 could have provided addi-
tional trial data on the relation between
glycemic control and well-being. In the
absence of such a contrast, we have had to
settle for the next-best solution regarding
this issue: cohort analysis of within-subject
changes in glycemic control as a determi-
nant of well-being, which had already been
planned for the analysis of changes in treat-
ment modality.
Despite the above-described experi-
mental results showing possible side effects
of setting stringent glycemic targets, these
further analyses suggest that in a popula-
tion with relatively well-controlled type 2
diabetes recruited from general practice,
further improvement in glycemic control
(independent of the effects of the random
target level) is generally accompanied by a
more favorable mood, overall satisfaction,
and well-being, but that the size of these
effects is not large. The relationship
between HbAlc and well-being we reported
earlier, based on cross-sectional data, is
confirmed by this prospective study (4).
Only in the prospective setting could
the psychological impact of initiating more
intensive treatment modalities (taking
tablets instead of diet alone, or starting daily
insulin injections) have been determined.
However, during 1 year of follow-up of this
study population, insulin was initiated in
only a small number of patients, so that the
estimates of the effects did not turn out to
be precise enough to allow any conclusions
on this issue. At first glance, the initiation of
insulin treatment seems associated with
unfavorable well-being, albeit not signifi-
cantly so in statistical terms: almost all of the
ORs in the right column of Table 3 are > 1.
Upon closer inspection of the crude values
of the 15 patients who initiated insulin
treatment, it appeared that the majority of
these patients reported no dramatic changes
in measures of well-being. For example, the
association we found between insulin being
started and general well-being (OR 3.73
[1.00-14.0], Table 3) appeared to have
come about through 3 people reporting
worse, 1 person reporting better, and 11
people reporting an equal score on this
scale. In addition, the OR is a relative meas-
ure, which means that an allegedly unfa-
vorable effect may be just an expression of
a lack of favorable effect relative to the rest
of the population.
Note that in this small subgroup, base-
line well-being was already worse (P = 0.05
for general well-being) than in the popula-
tion as a whole (Table 2). Although our
results were adjusted for baseline level, it
should be interesting to investigate in a
future study whether people with adverse
well-being react differently to initiation of
insulin treatment, as compared with people
with favorable well-being. Further longer-
term studies are required to assess whether
short-term adverse effects, if any, are tem-
porary. Interestingly, the step from dietary
measures alone to tablet treatment did not
have a favorable or unfavorable effect on
any well-being score used in our study.
Although the glycemic changes in our
already intensively treated population seem
small, one should keep in mind that the nat-
ural history of type 2 diabetes probably
would have led to slightly higher HbAlc lev-
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els after 1 year, instead of slightly lower ones
(26). A general problem posed by repeating
self-administered questionnaires after an
intervention is a possible change of the inter-
nal standard of measurement during fol-
low-up, creating so-called response shift bias
(22). This does have a role to play in inter-
preting changes in well-being scores in the
total population, but it does not prevent
comparison of changes between groups.
The association we found between the
HbAlc decrease and the neuropathic sensi-
bility symptom score is interesting with
respect to the often-cited clinical observa-
tion that neuropathic pain can increase
paradoxically upon institution of good
glycemic control, possibly attributable to
structural repair (23). In our population,
neuropathic pain symptoms were, however,
scarcer than sensibility symptoms. More-
over, the sensibility scale of the DSC-type 2
has been found to correlate with clinical and
neurophysiological assessments in known
diabetic neuropathy, while the neuropathic
pain scale did not correlate with these meas-
ures (24). The absence of an association
between the HbAlc decrease and the fatigue
and vigor scales of the POMS is consistent
with a similar absence for the fatigue scale of
the DSC-type 2 (Fig. 2 and Table 3).
By force, the results concerning the
HbA]c decrease were based on within-sub-
ject changes and not on a contrast attained
through randomization. Our observations
regarding the causes of the absence of a dif-
ference in glycemia at follow-up between
groups 6 and 8 are the subject of an as yet
unpublished study (EE.E.v.d.D., J.N.D.d.N.,
R.J.H., J.H. Dekker, L.M.B., unpublished
observations). Although the results of this
follow-up study are more convincing in
combination with our earlier cross-sectional
findings (4), this issue could be further
explored by establishing experimental con-
trasts, as is being done in studies currently
under way (25,26). There are some plausi-
ble explanations for discrepancies between
study results in this field, apart from the fact
that the alleged relation is simply not a
strong one and therefore inherently difficult
to confirm. Studies that found a relationship
between glycemic control and perceived
health (i.e., our study and a study by Nerenz
et al. [12]) included both men and women.
Previous negative studies included only men
(6,13,14). In our view, these negative results
could be attributable to floor effects, espe-
cially in men, in whom scores are generally
lower than in women (27). Furthermore,
discrepancies between studies might be
attributable to differences in severity of dis-
ease characteristics and complications. For
example, in an analysis similar to the pres-
ent, no relation was found within a popula-
tion where insulin use and multiple diabetic
complications were much more prevalent
(6). Finally, to our knowledge, there are no
other studies that have been able to adjust
for neuroticism, which is a major determi-
nant of well-being scores.
Of course, it is far from ideal that per-
sonality was assessed after 6 months
instead of at the beginning. We have found
no indication that neuroticism scores were
differentially affected by study participa-
tion: mean neuroticism scores in groups 6
and 8 were equal (12.0 vs. 13.2 on a 0-42
scale; P = 0.4).
Our findings are in accordance with
the idea that as to well-being, modest short-
term benefits of improved glycemic control
exist but may be paid for by less positive
feelings and/or an increased perceived bur-
den of treatment in some of the patients
allocated to strict target values for glycemic
control. This finding, although principally
not speaking against intensification of treat-
ment whenever considered necessary,
would call for individual stepwise target
setting to avoid frustration. No unaccept-
able hypoglycemic episodes occurred dur-
ing our study, reconfirming the relative
safety of intensification of treatment in type
2 diabetes. For the assessment of long-term
effects of changes in glycemic level, more
research is necessary not only on well-being
in the longer term but also on the onset of
late complications in type 2 diabetes (3).
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